The Stress- and Inflammatory Cytokine-induced Ectodomain Shedding of Heparin-binding Epidermal Growth Factor-like Growth Factor Is Mediated by p38 MAPK, Distinct from the 12-O-Tetradecanoylphorbol-13-acetate- and Lysophosphatidic Acid-induced Signaling Cascades*

Hisanori TakenobuDagger , Ayano YamazakiDagger , Michinari HirataDagger , Toshiyuki Umata§, and Eisuke MekadaDagger ||

From the Dagger  Department of Cell Biology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan and the § Institute of Life Science, Kurume University, Kurume, Fukuoka 839-0861, Japan

Received for publication, November 20, 2002, and in revised form, February 24, 2003

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a critical growth factor for a number of physiological and pathological processes. HB-EGF is synthesized as a membrane-anchored form (pro-HB-EGF), and pro-HB-EGF is cleaved at the cell surface to yield soluble HB-EGF by a mechanism called "ectodomain shedding." We show here that the ectodomain shedding of pro-HB-EGF in Vero cells is induced by various stress-inducing stimuli, including UV light, osmotic pressure, hyperoxidation, and translation inhibitors. The pro-inflammatory cytokine interleukin-1beta also stimulated the ectodomain shedding of pro-HB-EGF. An inhibitor of p38 MAPK (SB203580) or the expression of a dominant-negative (dn) form of p38 MAPK inhibited the stress-induced ectodomain shedding of pro-HB-EGF, whereas an inhibitor of JNK (SP600125) or the expression of dnJNK1 did not. 12-O-Tetradecanoylphorbol-13-acetate (TPA) and lysophosphatidic acid (LPA) are also potent inducers of pro-HB-EGF shedding in Vero cells. Stress-induced pro-HB-EGF shedding was not inhibited by the inhibitors of TPA- or LPA-induced pro-HB-EGF shedding or by dn forms of molecules involved in the TPA- or LPA-induced pro-HB-EGF shedding pathway. Reciprocally, SB203580 or dnp38 MAPK did not inhibit TPA- or LPA-induced pro-HB-EGF shedding. These results indicate that stress-induced pro-HB-EGF shedding is mediated by p38 MAPK and that the signaling pathway induced by stress is distinct from the TPA- or LPA-induced pro-HB-EGF shedding pathway.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Heparin-binding epidermal growth factor (EGF)1-like growth factor (HB-EGF) (1), a member of the EGF family, binds to the EGF receptor (ErbB1) and the related receptor tyrosine kinase (ErbB4) and activates them (2). HB-EGF, especially the secreted form (sHB-EGF), is a potent mitogen and chemoattractant for a number of cell types, including vascular smooth muscle cells, fibroblasts, and keratinocytes (3). HB-EGF is implicated in a number of physiological and pathological processes in the body (4), which include wound healing (5, 6), kidney collecting duct morphogenesis (7), blastocyst implantation (8), cardiac hypertrophy (9-11), smooth muscle cell hyperplasia (12), pulmonary hypertension (13), and oncogenic transformation (14).

HB-EGF, synthesized as a membrane-anchored precursor protein (pro-HB-EGF) of 208 amino acids, is composed of a signal peptide, a heparin-binding domain, an EGF-like region, a juxtamembrane domain, a transmembrane segment, and a cytoplasmic tail (3). Pro-HB-EGF is cleaved at the cell surface within the juxtamembrane domain through a process called ectodomain shedding, which results in secretion of a soluble 75-86-amino acid growth factor (sHB-EGF) (15). Although the regulated process of pro-HB-EGF ectodomain shedding yields substantial sHB-EGF, a considerable amount remains uncleaved at the cell surface. In addition to being a precursor of sHB-EGF, pro-HB-EGF is a biologically active molecule, forming a complex with both CD9 (16) and integrin alpha 3beta 1 (17) to transduce biological signals to neighboring cells in a non-diffusible manner (18). In contrast to the mitogenic effect of sHB-EGF (4), pro-HB-EGF negatively regulates cell proliferation (19). These results suggest that strict control of pro-HB-EGF ectodomain shedding is critical for the proper regulation of the activity of this growth factor.

Pro-HB-EGF ectodomain shedding is induced by both physiological and pharmacological agonists such as 12-O-tetradecanoylphorbol-13-acetate (TPA). TPA, an activator of protein kinase C (PKC), potently induces the ectodomain shedding of pro-HB-EGF (15) and of other membrane proteins (20). In monkey kidney Vero cells, the presence of a constitutively active form of PKCdelta results in the ectodomain shedding of pro-HB-EGF, and dominant-negative (dn) PKCdelta suppresses TPA-induced shedding, suggesting that the PKCdelta isoform contributes to the ectodomain shedding of pro-HB-EGF. PKCdelta binds to the cytoplasmic domain of ADAM9/MDC9/meltrin-gamma (21), a metalloprotease belonging to the ADAM (a disintegrin and metalloprotease) family (22). Overexpression of ADAM9 induces pro-HB-EGF shedding, which can be inhibited by the expression of the dnADAM9 mutant H347A,H351A in Vero-H cells. Thus, ADAM9 is thought to act downstream of PKCdelta in the pro-HB-EGF shedding pathway (21), although the role of this protease in the direct cleavage of pro-HB-EGF remains unclear.

Lysophosphatidic acid (LPA) and other ligands of the seven-transmembrane G protein-coupled receptors also stimulate pro-HB-EGF shedding (23, 24). The activation of shedding by such ligands is crucial for the transactivation of the EGF receptor by G protein-coupled receptor ligands (23, 25, 26). In Vero cells, the Ras-Raf-MEK and Rac signaling pathways are activated in LPA-induced shedding (27). LPA-induced shedding is inhibited by dnHa-Ras, dnRac1, and the MEK inhibitor PD98059, but not by either dnPKCdelta or dnADAM9. Conversely, although TPA-induced shedding is inhibited by dnPKCdelta and dnADAM9, such shedding is not affected by dnHa-Ras, dnRac1, and the MEK inhibitor. These results indicate that two distinct signaling pathways function to regulate pro-HB-EGF ectodomain shedding, here designated the LPA- and TPA-induced pathways.

Pro-HB-EGF expression is enhanced in various tissues upon injury and inflammation (28-35). The induction of this cellular response under these conditions suggests that HB-EGF is involved in both physiological tissue repair, including processes such as wound healing, and pathological processes, including atherosclerosis, that follow from inappropriate inflammation. Cellular stress and inflammation may function as triggers of ectodomain shedding. It remains unclear, however, if inflammatory cytokines and stimuli inducing cellular stress responses can trigger pro-HB-EGF ectodomain shedding. We demonstrate here that various stress-inducing stimuli and inflammatory cytokines strongly induce ectodomain shedding, acting through a p38 MAPK-mediated pathway, distinct from both the TPA- and LPA-induced signaling pathways. Our results suggest that HB-EGF activity is regulated at the transcriptional level and by ectodomain shedding, which responds to stress and inflammation.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Reagents-- TPA, Ro-31-8220, and anisomycin were purchased from Nacelle Tesque Co., Ltd. (Kyoto, Japan). LPA was obtained from Funakoshi Co., Ltd. (Tokyo, Japan). Recombinant human IL-1beta , human TNF-alpha , and mouse IL-6 were acquired from PeproTech (Rocky Hill, NJ). PD98059 and SB203580 were purchased from Calbiochem. SP600125 was obtained from BIOMOL Research Labs Inc. (Plymouth Meeting, PA). H2O2 was acquired from Santoku Chemical Industries Co., Ltd. (Tokyo). KB-R8301 was obtained from Nippon Organon K. K. (Osaka, Japan).

Antibodies-- The goat antibody specific for the C terminus of human pro-HB-EGF (C-18) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Goat anti-HB-EGF neutralizing antibody was obtained from R&D Systems. A rabbit antiserum against the N terminus of human pro-HB-EGF (H6) was derived as described (36). Rabbit anti-mouse ADAM9 antibody was raised against a glutathione S-transferase fusion protein containing the mouse ADAM9 C-terminal region (amino acids 718-845). Horseradish peroxidase-conjugated goat anti-rabbit and unconjugated anti-FLAG (M2) monoclonal antibodies were purchased from Zymed Laboratories Inc. and Sigma, respectively. Horseradish peroxidase- and Cy3-conjugated donkey anti-goat antibodies were obtained from Chemicon International, Inc. (Temecula, CA).

Plasmids-- pEGFP-c1, a plasmid encoding GFP, was purchased from Clontech. dnPKCdelta (R144A, R145A, K376R) (37, 38) and the mouse dnADAM9 mutant H347A,H351A (21) have been described previously. The FLAG-tagged mouse ADAM9 mutant E348A was generated by site-directed PCR-based mutagenesis. FLAG-tagged dnRac1 (N17Rac1) has been described previously (27). FLAG-tagged dnp38 MAPK (T180A,Y182F) was kindly provided by H. Hatanaka and Y. Ishikawa (Institute of Protein Research, Osaka University). pCMV5-JNK1(APF), a plasmid encoding FLAG-tagged dnJNK1 (39), and a constitutively active form of MKK6 (EE-MKK6) (40) were kindly provided by R. J. Davis (University of Massachusetts Medical School) and Y. Gotoh (University of Tokyo), respectively.

Cell Culture and Transfection-- Vero-H cells (15) were maintained in modified Eagle's medium with nonessential amino acids supplemented with 10% fetal calf serum. Transfections into Vero-H cells were performed using the calcium phosphate technique (41) unless otherwise stated.

Shedding Analysis by Western Blotting-- Vero-H cells (5 × 105 cells/6-cm dish) were cultured for 6-12 h in serum-free modified Eagle's medium with nonessential amino acids and then treated with TPA (64 nM), LPA (20 µg/ml), IL-1beta (4 ng/ml), anisomycin (10 µg/ml), sorbitol (0.4 M), or H2O2 (0.5 mM). When indicated, cells were also treated with either TNF-alpha (50 ng/ml) or IL-6 (20 ng/ml). For UV irradiation, Vero-H cells in 6-cm dishes in 3 ml of modified Eagle's medium with nonessential amino acids were exposed to 40 mJ/cm2 UV radiation (254 nm) using a Spectrolinker (Spectronics Corp.) Following incubation for 30 min with stimuli, cells were collected and resuspended in 140 µl of lysis buffer (1% Nonidet P-40, 50 mM Tris-HCl, 0.1 M NaCl, 10 mM MgCl2, 1 mM EDTA, 1 mM dithiothreitol, 0.2 mM phenylmethylsulfonyl fluoride, 20 µg/ml antipain, and 10 µg/ml chymostatin, pH 7.4). After 5 min on ice, the lysates were clarified by centrifugation at 15,000 rpm. Western blot analysis was performed using a goat antibody specific for the human pro-HB-EGF C terminus. The antibody was visualized with horseradish peroxidase-conjugated anti-goat IgG using ECL Plus (Amersham Biosciences). To detect sHB-EGF in the culture medium, sHB-EGF was trapped with heparin-Sepharose beads and then eluted with SDS gel sample buffer. The eluted materials were subjected to Western blot analysis and detected with rabbit anti-human HB-EGF antibody H6. The antibody was visualized with horseradish peroxidase-conjugated anti-rabbit IgG using ECL Plus.

Immunofluorescence Detection of the Shedding of the Pro-HB-EGF Ectodomain-- Pro-HB-EGF was detected on cells using goat anti-HB-EGF neutralizing antibody and Cy3-conjugated anti-goat IgG as described (21). To detect the expression of transfected proteins, fixed cells were permeabilized with 0.1% Triton X-100 for 3 min and then stained with anti-FLAG antibody or the antibodies indicated, followed by fluorescein isothiocyanate-conjugated second antibody. To detect cells transfected with dnPKCdelta or vector (pEF-BOS) alone as a control, EGFP (pEGFP-c1) was cotransfected. Images were captured with FISH ImagerTM system (Carl Zeiss, Inc.). The percentage of pro-HB-EGF-positive cells was determined by counting the number of pro-HB-EGF-positive cells among the total cells concomitantly expressing the products of the transfected cDNA. Values were determined based on the results obtained in at least two independent transfections from at least 100 independent cells positive for either the transfected or marker proteins in each experiment. Scoring was performed in a completely blind manner.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Stimuli Inducing Various Stresses and IL-1beta Lead to Pro-HB-EGF Shedding-- Vero-H cells are stable Vero transfectants overexpressing human pro-HB-EGF (15). This cell line exhibits consistent responses to stimuli inducing pro-HB-EGF ectodomain shedding (21, 24, 27). Using Vero-H cells, we examined the effect of pro-inflammatory cytokines and stress-inducing stimuli on the induction of pro-HB-EGF ectodomain shedding. First, we examined the ectodomain shedding of pro-HB-EGF by immunofluorescence microscopy using an antibody specific for the pro-HB-EGF ectodomain. Vero-H cells were pretreated with the indicated stimuli and then cultured for 30 min. Cells were treated with anti-HB-EGF neutralizing antibody and then fixed and visualized using a secondary antibody. Pro-HB-EGF fluorescence at the cell surface disappeared following addition of either LPA (20 µg/ml) or TPA (64 nM) to the culture medium (Fig. 1A) (21, 24, 27). In addition, the pro-inflammatory cytokine IL-1beta (4 µg/ml) also led to the disappearance of pro-HB-EGF surface immunofluorescence. Moreover, stimuli well known to induce a cellular stress response (42), such as translation inhibitors (anisomycin, 10 µg/ml) (43), exposure to UV light (40 mJ/cm2), hypertonic osmotic pressure (sorbitol, 0.4 M), or oxidative stress (H2O2, 0.5 mM), also induced the disappearance of pro-HB-EGF immunofluorescence from the cell surface.


View larger version (50K):
[in this window]
[in a new window]
 
Fig. 1.   Stress- and inflammatory cytokine-induced ectodomain shedding of pro-HB-EGF. Vero-H cells were treated with LPA (20 µg/ml), TPA (64 nM), IL-1beta (4 ng/ml), TNF-alpha (50 ng/ml), IL-6 (20 ng/ml), anisomycin (10 µg/ml), UV light (40 mJ/cm2), sorbitol (0.4 M), or H2O2 (0.5 mM) for 30 min, and then ectodomain shedding was detected by immunostaining of pro-HB-EGF and Western blot analysis. A, immunofluorescence detection of pro-HB-EGF at the cell surface. Cells were stained with anti-pro-HB-EGF neutralizing antibody, followed by Cy3-conjugated anti-goat IgG. The representative images for the samples treated with LPA, TPA, IL-1beta , anisomycin, UV light, sorbitol, and H2O2 are shown. The left panels are phase-contrast images, whereas the right panels are immunofluorescence images. B, Western blot analysis. The upper panel illustrates full-length pro-HB-EGF and the tail fragment within cell lysates, detected using an antibody raised against the pro-HB-EGF C terminus. The lower panel shows sHB-EGF appearing in the culture medium, detected using an antibody raised against the pro-HB-EGF N terminus.

Western blot analysis confirmed the ectodomain shedding of pro-HB-EGF in Vero-H cells (Fig. 1B). Immunoblot analysis of Vero-H cell lysates (upper panel) and the culture medium (lower panel) following incubation with the indicated stimuli detected the cytoplasmic domain of pro-HB-EGF and the shed soluble EGF-like domain, respectively. In cell lysates, bands ranging from 20 to 30 kDa correspond to pro-HB-EGF, whereas bands between 17.4 and 6.9 kDa are proteolytic fragments composed of the cytoplasmic and transmembrane domains of pro-HB-EGF (referred to as the "tail fragment"). Consistent with the appearance of the tail fragment, sHB-EGF appeared concurrently in the culture medium. These results indicate that IL-1beta , anisomycin, UV light, and sorbitol, in addition to LPA and TPA, induce pro-HB-EGF cleavage to generate both the tail fragment in cell lysates and sHB-EGF in the culture medium. Although H2O2 generated the tail fragment in cell lysates and sHB-EGF in the culture medium, this stimulus also reduced the total pro-HB-EGF protein present through an unknown mechanism. Centrifuging as a mimic of shearing stress also induced pro-HB-EGF ectodomain shedding (data not shown). In contrast, the pro-inflammatory cytokines TNF-alpha and IL-6 did not affect shedding. Rather, these cytokines reduced the total pro-HB-EGF protein, although the reduced level varied depending on the experiments.

We also examined the time course of pro-HB-EGF shedding induced by IL-1beta , anisomycin, UV light, and sorbitol. As the appearance of sHB-EGF in the culture medium correlated well with the appearance of the tail fragment in the cell lysate (Fig. 1B) (27), we utilized Western blot analysis only for the cell lysates to examine this event. As shown in Fig. 2, ectodomain shedding was observed following treatment with each of these stress stimuli at a time course similar to that observed for TPA-induced shedding (15, 21).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 2.   Time course of stress- and IL-1beta -induced ectodomain shedding. Vero-H cells were treated with 4 ng/ml IL-1beta (A), 10 µg/ml anisomycin (B), 40 mJ/cm2 UV light (C), or 0.4 M sorbitol (D). After the times indicated, the cells were harvested, and the cell lysates were analyzed by Western blotting with an antibody raised against the pro-HB-EGF C terminus.

Stress-induced Pro-HB-EGF Shedding Involves p38 MAPK-- Signals from pro-inflammatory cytokines and cellular responses to stress are generally mediated by SAPKs (42). Therefore, we hypothesized that stress-induced pro-HB-EGF shedding is mediated by a SAPK family kinase. We examined the activation of p38 MAPK and the various JNKs, major members of the SAPK family, following stress-inducing stimulation of Vero-H cells. After treatment with LPA, TPA, IL-1beta , anisomycin, UV irradiation, or sorbitol, Vero-H cell lysates were analyzed by Western blotting with either anti-phospho-p38 MAPK or anti-phospho-JNK antibody to monitor kinase phosphorylation status. Phosphorylated p38 MAPK was strongly observed after treatment with anisomycin, UV light, or sorbitol, with moderate increases in phosphorylation following treatment with either TPA or IL-1beta . SB203580, an inhibitor of p38 MAPK (44), significantly reduced p38 MAPK activity at a concentration of 2 µM (Fig. 3A). JNK1/2 and p38 MAPK were activated by treatment with LPA, TPA, IL-1beta , anisomycin, UV light, and sorbitol, although 2 µM SB203580 could not inhibit JNK1/2 phosphorylation (Fig. 3B). The results confirm that SB203580 specifically inhibits p38 MAPK activation. TNF-alpha and IL-6 could not activate either p38 MAPK (Fig. 3A) or JNK (Fig. 3B) in Vero-H cells, concurring with a lack of pro-HB-EGF cleavage (Fig. 1B).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of SB203580 on the activation of p38 MAPK and JNK1/2 or on pro-HB-EGF ectodomain shedding. Serum-starved Vero-H cells were pretreated with or without 2 µM SB203580 for 1 h. Cells were then treated with IL-1beta or stress-inducing or other stimuli for 30 min. Cell lysates were analyzed by Western blotting to detect activation of p38 MAPK and JNK1/2 and ectodomain shedding. A, activation level of p38 MAPK, detected with anti-phospho-p38 MAPK antibody (upper panels) and anti-p38 MAPK antibody (lower panels). B, activation level of JNK1/2, detected with anti-phospho-JNK1/2 antibody (upper panels) and anti-JNK1/2 antibody (lower panels). C, ectodomain shedding of pro-HB-EGF, detected by Western blotting using an antibody raised against the pro-HB-EGF C terminus.

We next inspected the SB203580 inhibition of pro-HB-EGF ectodomain shedding induction by IL-1beta , anisomycin, UV light, or sorbitol to verify the involvement of p38 MAPK. 2 µM SB203580 drastically inhibited the stress-induced shedding caused by IL-1beta , anisomycin, UV light, or sorbitol (Fig. 3C), whereas TPA- and LPA-induced shedding was not affected. Even concentrations of SB203580 in excess of 10 µM could not inhibit TPA- and LPA-induced shedding (data not shown). These results suggest that pro-HB-EGF ectodomain shedding induced by IL-1beta , anisomycin, UV light, or sorbitol requires p38 MAPK activation.

We examined the requirement for p38 MAPK in stress-induced pro-HB-EGF shedding using dnp38 MAPK. Following the transfection of FLAG-tagged dnp38 MAPK, cells were treated with various stimuli and then double-stained for pro-HB-EGF and dnp38 MAPK. Although treatment with IL-1beta , anisomycin, UV light, or sorbitol enhanced pro-HB-EGF shedding in vector-transfected cells (Fig. 4B), shedding was inhibited in FLAG-positive cells expressing dnp38 MAPK (Fig. 4, A and B). We confirmed that LPA- and TPA-induced pro-HB-EGF ectodomain shedding was not inhibited by dnp38 MAPK (Fig. 4B). MKK6 is a specific activator of p38 MAPK (45). Consistent with the role of the p38 MAPK pathway in shedding, transfection of a constitutively active form of MKK6 resulted in pro-HB-EGF ectodomain shedding in the absence of stress-inducing stimuli in a dose-dependent manner (Fig. 5). These results indicate that p38 MAPK activation is required for stress-induced pro-HB-EGF shedding in Vero-H cells.


View larger version (43K):
[in this window]
[in a new window]
 
Fig. 4.   Inhibition of stress- and IL-1beta -induced ectodomain shedding by dnp38 MAPK. A, Vero-H cells were transfected with a plasmid encoding FLAG-tagged dnp38 MAPK (20 µg) or with vector (18 µg) plus EGFP (2 µg) as a control. After 48 h of transfection, the cells were incubated with LPA, TPA, IL-1beta , anisomycin, UV light, or sorbitol and then double-stained with anti-HB-EGF antibody for the detection of the pro-HB-EGF ectodomain (red) and with anti-FLAG antibody for the detection of dnp38 MAPK expression (green). The right panels are phase-contrast images. Only the representative images of dnp38 MAPK-transfected cells are shown. B, shown is the percentage of pro-HB-EGF-positive cells among transfected cells, determined by immunofluorescence detection as shown in A. For vector-transfected cells, the percentage of pro-HB-EGF-positive cells among GFP-positive cells was determined.


View larger version (13K):
[in this window]
[in a new window]
 
Fig. 5.   Enhanced ectodomain shedding by a constitutively active form of MKK6. Vero-H cells were transfected with a plasmid encoding constitutively active (ca) MKK6 by electroporation (Bio-Rad, Gene Pulser) according to the manufacturer's instruction. The empty vector (pEF-BOS) and a plasmid encoding EGFP were also cotransfected at the amounts indicated. The percentage of pro-HB-EGF-positive cells among GFP-positive cells was determined.

SB203580 (2 µM) reduced the activity of p38 MAPK, but not that of JNK1/2, as shown in Fig. 3 (A and B). At the same concentration, SB203580 inhibited stress-induced shedding, suggesting that JNK is not involved in stress-induced shedding in Vero-H cells. To examine the involvement of JNK in stress-induced shedding directly, we tested whether SP600125, an inhibitor of JNK (46), abrogates stress-induced pro-HB-EGF shedding in Vero-H cells. SP600125 (5 µM) significantly reduced JNK1/2 phosphorylation caused by TPA, IL-1beta , anisomycin, and sorbitol treatment (Fig. 6A), whereas the same concentration of SP600125 could not inhibit p38 MAPK phosphorylation caused by IL-1beta , anisomycin, and sorbitol treatment (Fig. 6B). Based on these results, we tested whether SP600125 inhibits stress-induced ectodomain shedding in Vero-H cells. SP600125 (5 µM) did not inhibit pro-HB-EGF ectodomain shedding induced by any stimulus (Fig. 6C). In UV light-irradiated cells, JNK1/2 phosphorylation was strong and was not significantly reduced with 5 µM SP600125. SP600125 (20 µM) inhibited JNK1/2 phosphorylation caused by UV light, but SP600125 scarcely inhibited UV light-induced shedding even at this concentration.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of the JNK inhibitor SP600125 on stress-induced ectodomain shedding. Serum-starved Vero-H cells were pretreated with or without SP600125 at the indicated concentrations for 1 h and then treated with IL-1beta or stress-inducing or other stimuli for 30 min. Cell lysates were analyzed by Western blotting to detect activation of JNK1/2 and p38 MAPK and ectodomain shedding. A and B, activation levels of JNK1/2 and p38 MAPK, respectively. C, ectodomain shedding of pro-HB-EGF.

In addition to the JNK inhibitor, we used dnJNK1 to examine the involvement of the JNK pathway in stress-induced pro-HB-EGF shedding. Following the transfection of FLAG-tagged dnJNK1, cells were treated with various stimuli as Fig. 4B and then double-stained for pro-HB-EGF and dnJNK1. Pro-HB-EGF ectodomain shedding induced by each stimulus was not inhibited in FLAG-positive cells expressing dnJNK1 (Fig. 7). From these results, we conclude that the JNK pathway is not involved in stress-induced pro-HB-EGF ectodomain shedding in Vero-H cells.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 7.   Effects of dnJNK1 on stress-induced ectodomain shedding. Vero-H cells were transfected with a plasmid encoding FLAG-tagged dnJNK1 (20 µg) or with vector (pEF-BOS; 18 µg) plus EGFP (2 µg). After 48 h of transfection, the cells were incubated with LPA, TPA, IL-1beta , anisomycin, UV light, or sorbitol and then stained with anti-HB-EGF antibody for the detection of the pro-HB-EGF ectodomain. The expression of dnJNK1 was detected by anti-FLAG antibody. The percentage of pro-HB-EGF-positive cells among FLAG-positive cells was determined. For cells transfected with the empty vector, the percentage of pro-HB-EGF-positive cells among GFP-positive cells was determined.

p38 MAPK-mediated Shedding Cascades Are Independent of the Other Shedding Cascades-- Using Vero-H cells, we demonstrated that the LPA-induced shedding cascade involves the Ras-Raf-MEK and small GTPase Rac pathways, whereas TPA-induced pro-HB-EGF shedding involves PKCdelta and ADAM9. IL-1beta , anisomycin, and additional stresses induce shedding through a pathway involving the activation of p38 MAPK. We next analyzed the connection of the p38 MAPK-mediated pathway with either the LPA- or TPA-induced pathway. We tested the effect of the MEK inhibitor PD98059 (47) and the PKC inhibitor Ro-31-8220 (48) on p38 MAPK-mediated pro-HB-EGF ectodomain shedding. PD98059 inhibited LPA-induced, but not TPA-induced, shedding (Fig. 8A), whereas Ro-31-8220 inhibited TPA-induced, but not LPA-induced, shedding (Fig. 8B), confirming previous results (27). p38 MAPK-mediated stress-induced shedding was not inhibited by either PD98059 or Ro-31-8220. We also transfected dnPKCdelta or dnRac1. Neither dnPKCdelta nor dnRac1 inhibited p38 MAPK-mediated shedding, with the exception of partial inhibition observed for sorbitol-induced shedding by dnRac1 (Fig. 9). These data indicate that the stress-induced shedding cascade mediated by p38 MAPK activation functions independently of the LPA- and TPA-induced shedding cascades.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 8.   Effects of the MEK inhibitor PD98059 and the PKC inhibitor Ro-31-8220 on the ectodomain shedding of pro-HB-EGF. Serum-starved Vero-H cells were pretreated with 25 µM PD98059 (A) or 5 µM Ro-31-8220 (B) for 1 h. As a control, 0.1% Me2SO, the solvent of these inhibitors, was added. The cells were treated with each stimulus for 30 min. Ectodomain shedding was detected by Western blot analysis of cell lysates using an antibody raised against the pro-HB-EGF C terminus.


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 9.   Effects of dnRac1 and dnPKCdelta on the ectodomain shedding of pro-HB-EGF. Vero-H cells were transfected with plasmids encoding FLAG-tagged dnRac1 (20 µg) and dnPKCdelta (18 µg) plus EGFP (2 µg) or with vector (18 µg) plus EGFP (2 µg) as a control. After 48 h of transfection, the cells were incubated with LPA, TPA, IL-1beta , anisomycin, UV light, or sorbitol and then stained with anti-HB-EGF antibody for the detection of the pro-HB-EGF ectodomain. The expression of dnRac1 was detected by anti-FLAG antibody. The percentage of pro-HB-EGF-positive cells among FLAG-positive cells was determined. For cells transfected with either dnPKCdelta or the empty vector, the percentage of pro-HB-EGF-positive cells among GFP-positive cells was determined. ca, constitutively active.

Metalloproteases Are Involved in Stress-induced Shedding-- Metalloprotease inhibitors inhibit both TPA- and LPA-induced pro-HB-EGF shedding. We treated cells with a hydroxamic acid-based metalloprotease inhibitor, KB-R8301, to examine the role of metalloproteases in stress-induced shedding. KB-R8301 (10 µM) inhibited the pro-HB-EGF shedding induced by IL-1beta , anisomycin, UV light, H2O2, and sorbitol (Fig. 10A), indicating that metalloproteases are required for p38 MAPK-mediated pro-HB-EGF shedding as well.


View larger version (49K):
[in this window]
[in a new window]
 
Fig. 10.   Inhibition of stress- and IL-1beta -induced pro-HB-EGF shedding by the metalloprotease inhibitor KB-R8301, but not dnADAM9. A, effect of the metalloprotease inhibitor KB-R8301. Vero-H cells were pretreated with 10 µM KB-R8301 or 0.1% Me2SO for 1 h and then treated with each stimulus for 30 min. Ectodomain shedding was detected by Western blot analysis of cell lysates using an antibody raised against the pro-HB-EGF C terminus. B, effect of dnADAM9. Vero-H cells were transfected with plasmids encoding the dominant-negative mutants H347A,H351A (20 µg) and E348A (20 µg) or with vector alone (18 µg) plus EGFP (2 µg) as a control. After 48 h of transfection, cells were incubated with LPA, TPA, IL-1beta , UV light, or sorbitol and then double-stained with either anti-HB-EGF or anti-ADAM9 antibody. The percentage of pro-HB-EGF-positive cells among ADAM9-positive cells was determined. wt, wild-type.

ADAM family metalloproteases are involved in the ectodomain shedding of a variety of proteins such as TNF-alpha and Delta (49, 50). ADAM9 is known to be involved in TPA-induced pro-HB-EGF shedding in Vero-H cells (21). To examine the role of ADAM9 in p38 MAPK-mediated shedding, we examined the effect of overexpression of dnADAM9 on shedding. Two ADAM9 mutants were used, one carrying the modification of the conserved histidine residues in the catalytic domain to alanines (H347A,H351A) and the other carrying a modification of the conserved glutamic acid in the catalytic domain to alanine (E348A). We investigated the influence of these mutants on stress- and IL-1beta -induced shedding. Both mutants inhibited TPA-induced shedding, but did not affect LPA-, stress-, and IL-1beta -induced shedding (Fig. 10B). These results indicate that ADAM9 is not required for stress- and IL-1beta -induced pro-HB-EGF shedding in Vero-H cells.

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

HB-EGF contributes to tissue repair processes acting in response to various injuries (5, 6, 30, 51). HB-EGF also participates in pathological processes, including smooth muscle cell hyperplasia (12), restenosis following balloon injury (52), and cardiac hypertrophy (9-11). Ectodomain shedding is critical for the biological activity of this growth factor (53). In addition to regulation of growth factor activity, pro-HB-EGF ectodomain shedding contributes to the transactivation of the EGF receptor following ligation by G protein-coupled receptors and other ligands (23). Recent studies suggest that pro-HB-EGF ectodomain shedding and transactivation are involved in the pathological processes of cardiac hypertrophy and pulmonary hypertension (9, 13). Although a function for HB-EGF in physiological and pathological processes has been increasingly reported, information about shedding-inducing stimuli and the downstream signaling processes involved is limited (54). Two distinct signaling pathways contribute to pro-HB-EGF shedding in Vero-H cells, the TPA-induced PKCdelta - and ADAM9-mediated pathway and the LPA-induced MEK- and Rac-mediated pathway. Using Vero-H cells, we determined that various stress-inducing and inflammatory stimuli also trigger ectodomain shedding in a p38 MAPK-mediated manner. As this cascade does not require the activation of MEK, Rac, PKCdelta , or ADAM9, it appears to function independently of the TPA- and LPA-induced pathways. Thus, the p38 MAPK-mediated pathway is a third signal cascade that can induce pro-HB-EGF shedding in these cells.

Stress-induced ectodomain shedding is not specific to pro-HB-EGF. Osmotic stress induces L-selectin shedding in neutrophils (55). UV light and osmotic pressure promote the shedding of pro-transforming growth factor-alpha and proneuregulin in Chinese hamster ovary cells (56). Although stress activates both p38 MAPK and JNK, this and previous studies (55-57) suggest that p38 MAPK, rather than JNK, is the primary contributor to the stress-induced ectodomain shedding of a number of membrane proteins. Inflammatory cytokines, including TNF-alpha , IL-1beta , and IL-6, also stimulate membrane protein shedding (58-60). In Vero-H cells, however, neither ectodomain shedding nor p38 MAPK activation was observed following treatment with either TNF-alpha or IL-6 (Figs. 1B and 3A). Although it is possible that Vero-H cells do not bear the receptors ligating TNF-alpha and IL-6, it appears that signaling pathways induced by TNF-alpha and IL-6 do not contribute to pro-HB-EGF shedding.

We have demonstrated that stress- and IL-1beta -induced shedding requires protease(s) abrogated by metalloprotease inhibitors. This result is in agreement with data obtained for TPA- and LPA-induced shedding and for additional shedding cascades of transmembrane molecules (61). Therefore, a metalloprotease such as matrix metalloprotease or ADAM that works in close proximity to the membrane may participate in pro-HB-EGF shedding. The ADAM family metalloproteases contains a conserved sequence (HEXXH) that is a putative zinc-binding motif within the catalytic domain. We previously constructed a mutant form of ADAM9 (H347A,H351A, in which the conserved histidines are replaced with alanines) that was found to inhibit TPA-induced pro-HB-EGF shedding (21). Thus, ADAM9 is involved in pro-HB-EGF shedding induced by treatment of Vero-H cells with TPA. In this study, we constructed another dnADAM9 mutant (E348A) to examine its effect on TPA-induced pro-HB-EGF shedding. As E348A exhibited a subcellular localization similar to that of native ADAM9 when expressed in Vero-H cells, E348A may be a more suitable dnADAM9 mutant than the H347A,H351A mutant, which exhibited an altered localization pattern. Both dominant-negative mutants inhibited TPA-induced shedding, confirming the role of ADAM9 in TPA-induced shedding. Neither H347A, H351A nor E348A inhibited LPA-, stress-, or IL-1beta -induced pro-HB-EGF shedding in Vero-H cells. From these results, we conclude that ADAM9 does not participate in LPA-, stress-, or IL-1beta -induced pro-HB-EGF shedding.

Recent studies suggest that, in addition to ADAM9, ADAM10/Kuzbanian (13, 62), ADAM12/meltrin-alpha (9), and ADAM17/TACE (TNF-alpha converting enzyme) (63) function in pro-HB-EGF shedding in various cell systems. We therefore constructed putative dnADAM10, dnADAM12, and dnADAM17 mutants by substituting the conserved glutamic acid within the catalytic domain with an alanine (Glu mutants). These mutants were tested for their ability to inhibit stress- and IL-1beta -induced shedding in Vero-H cells. They did not prevent stress- and IL-1beta -induced pro-HB-EGF shedding in Vero-H cells.2 Although we have not confirmed the loss of catalytic activity by these constructed Glu mutants, these results suggest that ADAM10, ADAM12, and ADAM17 are not sheddases for stress- and IL-1beta -induced pro-HB-EGF shedding in Vero-H cells. Thus, the protease responsible for p38 MAPK-mediated pro-HB-EGF shedding in Vero-H cells remained to be identified.

What is the biological significance of stress-induced pro-HB-EGF shedding? A number of reports indicate that the transcription of pro-HB-EGF is up-regulated in response to oxidative, ischemic, osmotic, and mechanical stresses (29-34). The inflammatory cytokines IL-1beta and TNF-alpha also markedly increase pro-HB-EGF gene expression (35). The release of sHB-EGF from the membrane by ectodomain shedding is a prerequisite for the mitogenic activity as a paracrine and autocrine growth factor. Therefore, stress and inflammatory cytokines may also induce pro-HB-EGF shedding in addition to their transcriptional up-regulation. In response to stress and inflammation, HB-EGF activity may be regulated at both the transcriptional and ectodomain shedding levels. Considering the role of HB-EGF in tissue repair, the rapid release of sHB-EGF following stress-inducing stimuli may facilitate the repair of wounded tissues. These results also suggest that excess release of sHB-EGF by continual exposure of tissues to stress and inflammation may result in the pathological hyperplasia of cells such as smooth muscle and cardiac cells.

    FOOTNOTES

* This work was supported by the Research for the Future Program of the Japan Society for the Promotion of Science and by grants-in-aid from the Ministry of Education, Culture, Sports, Science, and Technology (to E. M.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Present address: Radioisotope Research Center, University of Occupational and Environmental Health, Kitakyushu 807-8555, Japan.

|| To whom correspondence should be addressed. Tel.: 81-6-6879-8286; Fax: 81-6-6879-8289; E-mail: emekada@biken.osaka-u.ac.jp.

Published, JBC Papers in Press, February 28, 2003, DOI 10.1074/jbc.M211835200

2 A. Yamazaki and E. Mekada, unpublished data.

    ABBREVIATIONS

The abbreviations used are: EGF, epidermal growth factor; HB-EGF, heparin-binding EGF-like growth factor; sHB-EGF, soluble HB-EGF; TPA, 12-O-tetradecanoylphorbol-13-acetate; PKC, protein kinase C; dn, dominant-negative; LPA, lysophosphatidic acid; MAPK, mitogen-activated protein kinase; MEK, MAPK/extracellular signal-regulated kinase kinase; MKK, MAPK kinase; IL, interleukin; TNF-alpha , tumor necrosis factor-alpha ; GFP, green fluorescent protein; EGFP, enhanced GFP; JNK, c-Jun N-terminal kinase; SAPK, stress-activated protein kinase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Higashiyama, S., Abraham, J. A., Miller, J., Fiddes, J. C., and Klagsbrun, M. (1991) Science 251, 936-939[Medline] [Order article via Infotrieve]
2. Elenius, K., Paul, S., Allison, G., Sun, J., and Klagsbrun, M. (1997) EMBO J. 16, 1268-1278[Abstract/Free Full Text]
3. Higashiyama, S., Lau, K., Besner, G. E., Abraham, J. A., and Klagsbrun, M. (1992) J. Biol. Chem. 267, 6205-6212[Abstract/Free Full Text]
4. Raab, G., and Klagsbrun, M. (1997) Biochim. Biophys. Acta 1333, F179-F199[CrossRef][Medline] [Order article via Infotrieve]
5. Marikovsky, M., Breuing, K., Liu, P. Y., Eriksson, E., Higashiyama, S., Farber, P., Abraham, J., and Klagsbrun, M. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3889-3893[Abstract]
6. Tokumaru, S., Higashiyama, S., Endo, T., Nakagawa, T., Miyagawa, J. I., Yamamori, K., Hanakawa, Y., Ohmoto, H., Yoshino, K., Shirakata, Y., Matsuzawa, Y., Hashimoto, K., and Taniguchi, N. (2000) J. Cell Biol. 151, 209-220[Abstract/Free Full Text]
7. Takemura, T., Hino, S., Kuwajima, H., Yanagida, H., Okada, M., Nagata, M., Sasaki, S., Barasch, J., Harris, R. C., and Yoshioka, K. (2001) J. Am. Soc. Nephrol. 12, 964-972[Abstract/Free Full Text]
8. Das, S. K., Wang, X. N., Paria, B. C., Damm, D., Abraham, J. A., Klagsbrun, M., Andrews, G. K., and Dey, S. K. (1994) Development 120, 1071-1083[Abstract/Free Full Text]
9. Asakura, M., Kitakaze, M., Takashima, S., Liao, Y., Ishikura, F., Yoshinaka, T., Ohmoto, H., Node, K., Yoshino, K., Ishiguro, H., Asanuma, H., Sanada, S., Matsumura, Y., Takeda, H., Beppu, S., Tada, M., Hori, M., and Higashiyama, S. (2002) Nat. Med. 8, 35-40[CrossRef][Medline] [Order article via Infotrieve]
10. Fujino, T., Hasebe, N., Fujita, M., Takeuchi, K., Kawabe, J., Tobise, K., Higashiyama, S., Taniguchi, N., and Kikuchi, K. (1998) Cardiovasc. Res. 38, 365-374[CrossRef][Medline] [Order article via Infotrieve]
11. Perrella, M. A., Maki, T., Prasad, S., Pimental, D., Singh, K., Takahashi, N., Yoshizumi, M., Alali, A., Higashiyama, S., and Kelly, R. A. (1994) J. Biol. Chem. 269, 27045-27050[Abstract/Free Full Text]
12. Miyagawa, J., Higashiyama, S., Kawata, S., Inui, Y., Tamura, S., Yamamoto, K., Nishida, M., Nakamura, T., Yamashita, S., Matsuzawa, Y., and Taniguchi, N. (1995) J. Clin. Invest. 95, 404-411[Medline] [Order article via Infotrieve]
13. Lemjabbar, H., and Basbaum, C. (2002) Nat. Med. 8, 41-46[CrossRef][Medline] [Order article via Infotrieve]
14. Fu, S., Bottoli, I., Goller, M., and Vogt, P. K. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 5716-5721[Abstract/Free Full Text]
15. Goishi, K., Higashiyama, S., Klagsbrun, M., Nakano, N., Umata, T., Ishikawa, M., Mekada, E., and Taniguchi, N. (1995) Mol. Biol. Cell 6, 967-980[Abstract]
16. Mitamura, T., Iwamoto, R., Umata, T., Yomo, T., Urabe, I., Tsuneoka, M., and Mekada, E. (1992) J. Cell Biol. 118, 1389-1399[Abstract]
17. Nakamura, K., Iwamoto, R., and Mekada, E. (1995) J. Cell Biol. 129, 1691-1705[Abstract]
18. Higashiyama, S., Iwamoto, R., Goishi, K., Raab, G., Taniguchi, N., Klagsbrun, M., and Mekada, E. (1995) J. Cell Biol. 128, 929-938[Abstract]
19. Iwamoto, R., Handa, K., and Mekada, E. (1999) J. Biol. Chem. 274, 25906-25912[Abstract/Free Full Text]
20. Arribas, J., Coodly, L., Vollmer, P., Kishimoto, T. K., Rose-John, S., and Massagué, J. (1996) J. Biol. Chem. 271, 11376-11382[Abstract/Free Full Text]
21. Izumi, Y., Hirata, M., Hasuwa, H., Iwamoto, R., Umata, T., Miyado, K., Tamai, Y., Kurisaki, T., Sehara-Fujisawa, A., Ohno, S., and Mekada, E. (1998) EMBO J. 17, 7260-7272[Abstract/Free Full Text]
22. Weskamp, G., Kratzschmar, J., Reid, M. S., and Blobel, C. P. (1996) J. Cell Biol. 132, 717-726[Abstract]
23. Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R., Wallasch, C., and Ullrich, A. (1999) Nature 402, 884-888[CrossRef][Medline] [Order article via Infotrieve]
24. Hirata, M., Umata, T., Takahashi, T., Ohnuma, M., Miura, Y., Iwamoto, R., and Mekada, E. (2001) Biochem. Biophys. Res. Commun. 283, 915-922[CrossRef][Medline] [Order article via Infotrieve]
25. Eguchi, S., Dempsey, P. J., Frank, G. D., Motley, E. D., and Inagami, T. (2001) J. Biol. Chem. 276, 7957-7962[Abstract/Free Full Text]
26. Fujiyama, S., Matsubara, H., Nozawa, Y., Maruyama, K., Mori, Y., Tsutsumi, Y., Masaki, H., Uchiyama, Y., Koyama, Y., Nose, A., Iba, O., Tateishi, E., Ogata, N., Jyo, N., Higashiyama, S., and Iwasaka, T. (2001) Circ. Res. 88, 22-29[Abstract/Free Full Text]
27. Umata, T., Hirata, M., Takahashi, T., Ryu, F., Shida, S., Takahashi, Y., Tsuneoka, M., Miura, Y., Masuda, M., Horiguchi, Y., and Mekada, E. (2001) J. Biol. Chem. 276, 30475-30482[Abstract/Free Full Text]
28. Blotnick, S., Peoples, G. E., Freeman, M. R., Eberlein, T. J., and Klagsbrun, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2890-2894[Abstract]
29. Koh, Y. H., Che, W., Higashiyama, S., Takahashi, M., Miyamoto, Y., Suzuki, K., and Taniguchi, N. (2001) J. Biochem. (Tokyo) 130, 351-358[Abstract]
30. Fang, L., Li, G., Liu, G., Lee, S. W., and Aaronson, S. A. (2001) EMBO J. 20, 1931-1939[Abstract/Free Full Text]
31. Miyazaki, Y., Hiraoka, S., Tsutsui, S., Kitamura, S., Shinomura, Y., and Matsuzawa, Y. (2001) Gastroenterology 120, 108-116[Medline] [Order article via Infotrieve]
32. Sakai, M., Tsukada, T., and Harris, R. C. (2001) Exp. Nephrol. 9, 28-39[CrossRef][Medline] [Order article via Infotrieve]
33. Nguyen, H. T., Adam, R. M., Bride, S. H., Park, J. M., Peters, C. A., and Freeman, M. R. (2000) Am. J. Physiol. 279, C1155-C1167
34. Morita, T., Yoshizumi, M., Kurihara, H., Maemura, K., Nagai, R., and Yazaki, Y. (1993) Biochem. Biophys. Res. Commun. 197, 256-262[CrossRef][Medline] [Order article via Infotrieve]
35. Yoshizumi, M., Kourembanas, S., Temizer, D. H., Cambria, R. P., Quertermous, T., and Lee, M. E. (1992) J. Biol. Chem. 267, 9467-9469[Abstract/Free Full Text]
36. Iwamoto, R., Higashiyama, S., Mitamura, T., Taniguchi, N., Klagsbrun, M., and Mekada, E. (1994) EMBO J. 13, 2322-2330[Abstract]
37. Hirai, S., Izumi, Y., Higa, K., Kaibuchi, K., Mizuno, K., Osada, S., Suzuki, K., and Ohno, S. (1994) EMBO J. 13, 2331-2340[Abstract]
38. Ohno, S., Mizuno, K., Adachi, Y., Hata, A., Akita, Y., Akimoto, K., Osada, S., Hirai, S., and Suzuki, K. (1994) J. Biol. Chem. 269, 17495-17501[Abstract/Free Full Text]
39. Derijard, B., Hibi, M., Wu, I. H., Barrett, T., Su, B., Deng, T., Karin, M., and Davis, R. J. (1994) Cell 76, 1025-1037[Medline] [Order article via Infotrieve]
40. Fujishiro, M., Gotoh, Y., Katagiri, H., Sakoda, H., Ogihara, T., Anai, M., Onishi, Y., Ono, H., Funaki, M., Inukai, K., Fukushima, Y., Kikuchi, M., Oka, Y., and Asano, T. (2001) J. Biol. Chem. 276, 19800-19806[Abstract/Free Full Text]
41. Chen, C., and Okayama, H. (1987) Mol. Cell. Biol. 7, 2745-2752[Medline] [Order article via Infotrieve]
42. Kyriakis, J. M., and Avruch, J. (2001) Physiol. Rev. 81, 807-869[Abstract/Free Full Text]
43. Cano, E., Hazzalin, C. A., and Mahadevan, L. C. (1994) Mol. Cell. Biol. 14, 7352-7362[Abstract]
44. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, D., McNulty, D., Blumenthal, M. J., Heys, J. R., Landvatter, S. W., Strickler, J. E., McLaughlin, M. M., Siemens, I. R., Fisher, S. M., Livi, G. P., White, J. R., Adams, J. L., and Young, P. R. (1994) Nature 372, 739-746[CrossRef][Medline] [Order article via Infotrieve]
45. Han, J., Lee, J. D., Jiang, Y., Li, Z., Feng, L., and Ulevitch, R. J. (1996) J. Biol. Chem. 271, 2886-2891[Abstract/Free Full Text]
46. Bennett, B. L., Sasaki, D. T., Murray, B. W., O'Leary, E. C., Sakata, S. T., Xu, W., Leisten, J. C., Motiwala, A., Pierce, S., Satoh, Y., Bhagwat, S. S., Manning, A. M., and Anderson, D. W. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 13681-13686[Abstract/Free Full Text]
47. Dudley, D. T., Pang, L., Decker, S. J., Bridges, A. J., and Saltiel, A. R. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7686-7689[Abstract]
48. Bradshaw, D., Hill, C. H., Nixon, J. S., and Wilkinson, S. E. (1993) Agent Actions 38, 135-147[Medline] [Order article via Infotrieve]
49. Blobel, C. P. (2000) Curr. Opin. Cell Biol. 12, 606-612[CrossRef][Medline] [Order article via Infotrieve]
50. Black, R. A., and White, J. M. (1998) Curr. Opin. Cell Biol. 10, 654-659[CrossRef][Medline] [Order article via Infotrieve]
51. Michalsky, M. P., Kuhn, A., Mehta, V., and Besner, G. E. (2001) J. Pediatr. Surg. 36, 1130-1135[CrossRef][Medline] [Order article via Infotrieve]
52. Igura, T., Kawata, S., Miyagawa, J., Inui, Y., Tamura, S., Fukuda, K., Isozaki, K., Yamamori, K., Taniguchi, N., Higashiyama, S., and Matsuzawa, Y. (1996) Arterioscler. Thromb. Vasc. Biol. 16, 1524-1531[Abstract/Free Full Text]
53. Iwamoto, R., and Mekada, E. (2000) Cytokine Growth Factor Rev. 11, 335-344[CrossRef][Medline] [Order article via Infotrieve]
54. Gechtman, Z., Alonso, J. L., Raab, G., Ingber, D. E., and Klagsbrun, M. (1999) J. Biol. Chem. 274, 28828-28835[Abstract/Free Full Text]
55. Rizoli, S. B., Rotstein, O. D., and Kapus, A. (1999) J. Biol. Chem. 274, 22072-22080[Abstract/Free Full Text]
56. Montero, J. C., Yuste, L., Diaz-Rodriguez, E., Esparis-Ogando, A., and Pandiella, A. (2002) Biochem. J. 363, 211-221[CrossRef][Medline] [Order article via Infotrieve]
57. Fan, H., and Derynck, R. (1999) EMBO J. 18, 6962-6972[Abstract/Free Full Text]
58. Franzke, C. W., Tasanen, K., Schacke, H., Zhou, Z., Tryggvason, K., Mauch, C., Zigrino, P., Sunnarborg, S., Lee, D. C., Fahrenholz, F., and Bruckner-Tuderman, L. (2002) EMBO J. 21, 5026-5035[Abstract/Free Full Text]
59. Levine, S. J., Logun, C., Chopra, D. P., Rhim, J. S., and Shelhamer, J. H. (1996) Am. J. Respir. Cell Mol. Biol. 14, 254-261[Abstract]
60. Yabkowitz, R., Meyer, S., Black, T., Elliott, G., Merewether, L. A., and Yamane, H. K. (1999) Blood 93, 1969-1979[Abstract/Free Full Text]
61. Hooper, N. M., Karran, E. H., and Turner, A. J. (1997) Biochem. J. 321, 265-279[Medline] [Order article via Infotrieve]
62. Yan, Y., Shirakabe, K., and Werb, Z. (2002) J. Cell Biol. 158, 221-226[Abstract/Free Full Text]
63. Sunnarborg, S. W., Hinkle, C. L., Stevenson, M., Russell, W. E., Raska, C. S., Peschon, J. J., Castner, B. J., Gerhart, M. J., Paxton, R. J., Black, R. A., and Lee, D. C. (2002) J. Biol. Chem. 277, 12838-12845[Abstract/Free Full Text]


Copyright © 2003 by The American Society for Biochemistry and Molecular Biology, Inc.